Compositions, methods of use, and methods of treatment
Embodiments of the present disclosure provide for compositions including an antimicrobial agent, pharmaceutical compositions including the composition or pharmaceutical composition, methods of treating a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
1. A composition, consisting of a COX-2 inhibitor and a cannabinoid.
2. The composition of claim 1 , wherein the COX-2 inhibitor is selected from the group consisting of: celecoxib, rofecoxib, meloxicam, piroxicam, deracoxib, parecoxib, valdecoxib, etoricoxib, a chromene derivative, a chroman derivative, N-(2-cyclohexyloxynitrophenyl)methane sulfonamide, COX189, ABT963, JTE-522, rofecoxib, valdecoxib, parecoxib, aspirin, acetaminophen, ibuprofen, flurbiprofen, ketoprofen, naproxen, oxaprozin, etodolac, indomethacin, ketorolac, lornoxicam, nabumetone, and diclofenac, and pharmaceutically acceptable salts of each.
3. The composition of claim 1 , wherein the cannabinoid is selected from the group consisting of: dronabinol, nabilone, cannabinol (CBN), tetrahydrocannabinol (THC), dimethyl heptylpentyl cannabidiol (DMHP-CBD).
4. The composition of claim 1 , wherein the COX-2 inhibitor is celecoxib or rofecoxib and the cannabinoid is dronabinol and or nabilone.
5. A pharmaceutical composition consisting of a COX-2 inhibitor, or a pharmaceutically acceptable salt of the COX-2 inhibitor, a cannabinoid, or a pharmaceutically acceptable salt of the cannabinoid, and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition consisting essentially of a COX-2 inhibitor or a pharmaceutically acceptable salt of the COX-2 inhibitor, a cannabinoid or a pharmaceutically acceptable salt of the cannabinoid, and a pharmaceutically acceptable carrier; wherein the cannabinoid is formulated in a delayed release formulation.
7. The pharmaceutical composition of claim 5 , wherein the COX-2 inhibitor is selected from the group consisting of: celecoxib, rofecoxib, meloxicam, piroxicam, deracoxib, parecoxib, valdecoxib, etoricoxib, a chromene derivative, a chroman derivative, N-(2-cyclohexyloxynitrophenyl)methane sulfonamide, COX189, ABT963, JTE-522, rofecoxib, valdecoxib, parecoxib, aspirin, acetaminophen, ibuprofen, flurbiprofen, ketoprofen, naproxen, oxaprozin, etodolac, indomethacin, ketorolac, lornoxicam, nabumetone, and diclofenac, as well as pharmaceutically acceptable salts of each.
8. The pharmaceutical composition of claim 5 , wherein the cannabinoid is selected from the group consisting of: dronabinol, nabilone, cannabinol (CBN), tetrahydrocannabinol (THC), dimethyl heptylpentyl cannabidiol (DMHP-CBD).
9. The pharmaceutical composition of claim 5 , wherein the COX-2 inhibitor is celecoxib or rofecoxib and the cannabinoid is dronabinol or nabilone.